WallStSmart

Abeona Therapeutics Inc (ABEO)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 10320% more annual revenue ($606.42M vs $5.82M). ABEO leads profitability with a 12.2% profit margin vs -2.1%. ABEO earns a higher WallStSmart Score of 43/100 (D).

ABEO

Hold

43

out of 100

Grade: D

Growth: 5.3Profit: 5.0Value: 8.3Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABEOUndervalued (+38.5%)

Margin of Safety

+38.5%

Fair Value

$8.23

Current Price

$4.42

$3.81 discount

UndervaluedFair: $8.23Overvalued

Intrinsic value data unavailable for INSM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABEO3 strengths · Avg: 9.3/10
P/E RatioValuation
3.7x10/10

Attractively priced relative to earnings

Return on EquityProfitability
70.1%10/10

Every $100 of equity generates 70 in profit

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ABEO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$241.15M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-100.0%2/10

Revenue declined 100.0%

Free Cash FlowQuality
$-19.11M2/10

Negative free cash flow — burning cash

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABEO

The strongest argument for ABEO centers on P/E Ratio, Return on Equity, Price/Book.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : ABEO

The primary concerns for ABEO are EPS Growth, Market Cap, Revenue Growth.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

ABEO profiles as a declining stock while INSM is a turnaround play — different risk/reward profiles.

ABEO carries more volatility with a beta of 1.19 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

ABEO generates stronger free cash flow (-19M), providing more financial flexibility.

Bottom Line

ABEO scores higher overall (43/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abeona Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?